Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.

Hidalgo, O F

Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. [electronic resource] - Revista de medicina de la Universidad de Navarra - 6-12 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article

0556-6177


Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Renal Cell--secondary
Drug Administration Schedule
Female
Fever--chemically induced
Humans
Hypotension--chemically induced
Immunologic Factors--administration & dosage
Infusions, Intravenous
Injections, Subcutaneous
Interferon-alpha--administration & dosage
Interleukin-2--administration & dosage
Kidney Neoplasms--pathology
Male
Melanoma--secondary
Middle Aged
Recombinant Proteins--administration & dosage
Skin Neoplasms--pathology
Survival Analysis
Treatment Outcome